These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 8739323)
1. Effect of some anticancer drugs and combined chemotherapy on renal toxicity. Skretkowicz J; Sekulska M; Danilewicz M; Wagrowska-Danilewicz M; Polakowski P Biol Signals; 1996; 5(1):51-8. PubMed ID: 8739323 [TBL] [Abstract][Full Text] [Related]
2. Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat. Skretkowicz J Pol J Pharmacol; 1995; 47(6):519-24. PubMed ID: 8868374 [TBL] [Abstract][Full Text] [Related]
3. The CMF-regimen. Toxicity patterns following stepwise combinations of cyclophosphamide, methotrexate and fluorouracil. De Bruijn EA; Driessen OM; Hermans J Int J Cancer; 1991 Apr; 48(1):67-72. PubMed ID: 2019458 [TBL] [Abstract][Full Text] [Related]
4. The CMF-regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil. De Bruijn EA; Geng Y; Hermans J; Driessen O Int J Cancer; 1990 May; 45(5):935-9. PubMed ID: 2335396 [TBL] [Abstract][Full Text] [Related]
5. Fluorouracil catabolism in the combination treatment of cyclophosphamide, methotrexate and fluorouracil. De Bruijn EA; Van der Heyden SA; Gheuens EE; Maes RA Jpn J Cancer Res; 1992 Oct; 83(10):1102-7. PubMed ID: 1452462 [TBL] [Abstract][Full Text] [Related]
6. Histopathological and biochemical assessment of kidney damage in albino wistar rats treated with cytotoxic platinum compounds in combination with 5-FU. Bano N; Ikram R Pak J Pharm Sci; 2017 Sep; 30(5):1595-1601. PubMed ID: 29084678 [TBL] [Abstract][Full Text] [Related]
7. Effect of diets on 5-fluorouracil and cyclophosphamide toxicity. Chevreau N; Wang Y; Funk-Archuleta M Nutr Cancer; 1995; 23(2):205-20. PubMed ID: 7644388 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of cyclophosphamide in the CMF regimen. Gheuens E; Slee PH; de Bruijn EA Onkologie; 1990 Jun; 13(3):203-6. PubMed ID: 2204007 [TBL] [Abstract][Full Text] [Related]
9. Toxicity, pathological effects, and antineoplastic activity of a non-toxic dose of 5-fluorouracil in combination with methotrexate. Robbins TJ; Bowen D Anticancer Res; 1988; 8(1):43-9. PubMed ID: 3358639 [TBL] [Abstract][Full Text] [Related]
10. Vitamin E protects intestinal basolateral membrane from CMF-induced damages in rat. Subramaniam S; Subramaniam S; Shyamala Devi CS Indian J Physiol Pharmacol; 1995 Jul; 39(3):263-6. PubMed ID: 8550122 [TBL] [Abstract][Full Text] [Related]
11. Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats. Çağlar Y; Özgür H; Matur I; Yenilmez ED; Tuli A; Gönlüşen G; Polat S Histol Histopathol; 2013 Jul; 28(7):865-74. PubMed ID: 23307329 [TBL] [Abstract][Full Text] [Related]
12. [Experimental toxicologic and therapeutic studies on the activity of the CMF(cyclophosphamide-methotrexate-5-fluorouracil) scheme versus the VMF(vincristine-methotrexate-5-fluorouracil) scheme]. Berger MR; Habs M; Schmähl D Arch Geschwulstforsch; 1984; 54(4):263-78. PubMed ID: 6548622 [TBL] [Abstract][Full Text] [Related]
13. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Kolli VK; Abraham P; Isaac B; Selvakumar D Chemotherapy; 2009; 55(2):83-90. PubMed ID: 19145077 [TBL] [Abstract][Full Text] [Related]
14. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Abraham P; Kolli VK; Rabi S Cell Biochem Funct; 2010 Jul; 28(5):426-33. PubMed ID: 20589739 [TBL] [Abstract][Full Text] [Related]
15. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. Hirakata Y; Furuya N; Matsumoto T; Tateda K; Yamaguchi K J Med Microbiol; 1995 Mar; 42(3):181-5. PubMed ID: 7533840 [TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Schmid FA; Sirotnak FM; Otter GM; DeGraw JI Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Batey MA; Wright JG; Azzabi A; Newell DR; Lind MJ; Calvert AH; Boddy AV Eur J Cancer; 2002 May; 38(8):1081-9. PubMed ID: 12008196 [TBL] [Abstract][Full Text] [Related]
18. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity. Ibrahim MA; El-Sheikh AA; Khalaf HM; Abdelrahman AM Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):130-7. PubMed ID: 24521009 [TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534 [TBL] [Abstract][Full Text] [Related]
20. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Asvadi I; Hajipour B; Asvadi A; Asl NA; Roshangar L; Khodadadi A Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1003-9. PubMed ID: 22013722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]